Skip to main content

Table 3 Main pharmacokinetic parameters of all groups

From: Screening for an ivermectin slow-release formulation suitable for malaria vector control

Group

Mean daily dose

Tmax

Cmax

AUC 12 weeks

AUC 24 weeks

Time >7 ng/ml

1 F

64 (60–77)

2 (1–2)

7 (7–10)

66 (61–68)

-

3 (1–3)

2 F

76 (75–105)

1 (1–2)

16 (12–16)

120 (113–163)

-

12 (11–12)

3 F

75 (70–85)

1 (1–2)

22 (19–36)

155 (153–348)

277 (266–615)

24 (24)

1 M

34 (31–43)

7 (7–11)

13 (4–20)

81 (38–126)

-

3 (0–11)

2 M

83 (77–91)

2 (1–3)

16 (14–20)

122 (106–164)

-

12 (8–12)

3 M

69 (63–73)

1 (1–2)

22 (16–33)

164 (160–224)

300 (278–403)

24 (24)

1X

30 (29–32)

3 (2–8)

12 (8–14)

79 (63–85)

-

2 (1–3)

2X

30 (27–34)

4 (3–4)

17 (17–35)

170 (152–311)

218 (207–404)

12 (12–16)

3X

43 (41–49)

3 (2–7)

42 (35–85)

307 (306–497)

422 (393–620)

16 (16)

  1. For all values median and range are given. Mean daily dose (μg/kg/day), Tmax (weeks), Cmax (ng/ml), AUC (ng · week/ml), Time above 7 ng/ml (weeks).